S
Serena Vegna
Researcher at Netherlands Cancer Institute
Publications - 16
Citations - 548
Serena Vegna is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Medicine & Viral replication. The author has an hindex of 8, co-authored 12 publications receiving 244 citations. Previous affiliations of Serena Vegna include University of Lyon & University of Montpellier.
Papers
More filters
Journal ArticleDOI
Inducing and exploiting vulnerabilities for the treatment of liver cancer.
Cun Wang,Cun Wang,Serena Vegna,Haojie Jin,Haojie Jin,Bente Benedict,Cor Lieftink,Christel Ramirez,Rodrigo Leite de Oliveira,Ben Morris,Jules Gadiot,Wei Wang,Aimee du Chatinier,Liqin Wang,Dongmei Gao,Bastiaan Evers,Guangzhi Jin,Zheng Xue,Arnout Schepers,Fleur Jochems,Antonio Mulero Sanchez,Sara Mainardi,Hein te Riele,Roderick L. Beijersbergen,Wenxin Qin,Leila Akkari,René Bernards +26 more
TL;DR: Using multiple in vivo mouse models of liver cancer, treatment with combined inhibition of of CDC7 and mTOR results in a marked reduction of tumour growth, indicating that exploiting an induced vulnerability could be an effective treatment for liver cancer.
Journal ArticleDOI
EGFR activation limits the response of liver cancer to lenvatinib.
Haojie Jin,Haojie Jin,Yaoping Shi,Yuanyuan Lv,Shengxian Yuan,Christel Ramirez,Cor Lieftink,Liqin Wang,Siying Wang,Cun Wang,Matheus H. Dias,Fleur Jochems,Yuan Yang,Astrid Bosma,E. Marielle Hijmans,Marnix H. P. de Groot,Serena Vegna,Dan Cui,Yangyang Zhou,Jing Ling,Hui Wang,Yuchen Guo,Xingling Zheng,Nikita Isima,Haiqiu Wu,Chong Sun,Chong Sun,Roderick L. Beijersbergen,Leila Akkari,Weiping Zhou,Bo Zhai,Wenxin Qin,ReneÌ Bernards +32 more
TL;DR: In this article, the combination of the EGFR inhibitor gefitinib and lenvatinib displays potent anti-proliferative effects in vitro in liver cancer cell lines that express EGFR and in vivo in xenografted liver cancer cells lines, immunocompetent mouse models and patient-derived HCC tumours in mice.
Journal ArticleDOI
Understanding the Origin and Diversity of Macrophages to Tailor Their Targeting in Solid Cancers.
TL;DR: Multiple macrophage-targeting strategies in brain, liver, and lung cancers, which all emerge in tissues rich in resident macrophages are reviewed, and the successes and failures of these therapeutic approaches are discussed.
Journal ArticleDOI
Characterization of Pattern Recognition Receptor Expression and Functionality in Liver Primary Cells and Derived Cell Lines.
Suzanne Faure-Dupuy,Serena Vegna,Ludovic Aillot,Laura Dimier,Knud Esser,Mathias Broxtermann,Marc Bonnin,Nathalie Bendriss-Vermare,Michel Rivoire,Guillaume Passot,Mickael Lesurtel,Jean-Yves Mabrut,Christian Ducerf,Anna Salvetti,Ulrike Protzer,Fabien Zoulim,David Durantel,Julie Lucifora +17 more
TL;DR: By generating a cell line that retained higher innate immune functionality as compared to THP1 cells, this work will help to understand immune mechanisms behind antiviral effects of TLR agonists or checkpoint inhibitors, which are in current preclinical or clinical development.
Journal ArticleDOI
NOD1 Participates in the Innate Immune Response Triggered by Hepatitis C Virus Polymerase.
Serena Vegna,Damien Grégoire,Damien Grégoire,Marie Moreau,Marie Moreau,Patrice Lassus,Patrice Lassus,David Durantel,Eric Assenat,Eric Assenat,Urszula Hibner,Urszula Hibner,Yannick Simonin +12 more
TL;DR: NOD1, a PRR that normally senses bacterial peptidoglycans, is activated by HCV viral polymerase, probably through an interaction with dsRNA, suggesting that NOD1 acts as an RNA ligand recognition receptor, which significantly weakens the inflammatory response to ds RNA.